Specialty Pharmacy May 15, 2023 Thoughts Following Asembia 2023 Part 1: Exploring the New Pharmacy Landscape 2 Minute Read Channel expert Bill Roth explores how specialty pharmacy has evolved and their take on the current landscape and insights for pharmaceutical organizations.
Contracts & Pricing April 24, 2023 340B Contract Pharmacy Restrictions, M&A Funding in Biotech & FDA Accelerated... 6 Minute Read Updates on 340B Contract Pharmacy Restriction Updates, M&A and Venture Capital Funding in Biotech, and Stricter Accelerated Approval Criteria Proposed for FDA.
Gross-to-Net April 17, 2023 Why Modernize Your Gross-to-Net? 5 Benefits of Pharma Digital Transformation 2 Minute Read In the current pharma landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. This is primarily because of...
Government Pricing April 7, 2023 State Pricing Transparency Reporting – Part 2 3 Minute Read Explore the best practice recommendations regarding compliance for SPTR.
Contracts & Pricing March 29, 2023 Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act Guidance... 5 Minute Read Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act, and Operationalizing Medicare Inflationary Rebates.
Launch Readiness March 21, 2023 Perspectives on Pharma Market Access Launch Challenges & Strategy Part 2 9 Minute Read We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
Gross-to-Net March 6, 2023 5 Pharma Gross-to-Net Questions You Should Be Asking 4 Minute Read Whether manufacturers are entering new therapeutic categories, exploring new indications for a current product, or looking to acquire a new product through acquisition, managing Gross-To-Net can be complex.
Contracts & Pricing February 27, 2023 FDA Set to Apply Orphan-Drug Exclusivity, 2022 Employer Health Benefits Survey... 5 Minute Read Updates on two significant regulatory topics, including the FDA decision on orphan-drug exclusivity regulations and highlights from the Kaiser Family Foundation 2022 Employer Benefits Survey.
Launch Readiness February 7, 2023 Perspectives on Pharma Market Access Launch Challenges & Strategy Part 1 5 Minute Read We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.